Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280687 | 0.79 | OPRM1 (1.00) | OPRL1OPRM1OPRK1DRD2SLC6A4 | |
| SCHEMBL14529394 | 0.77 | DRD2 (0.50) | OPRL1OPRM1OPRK1DRD2SLC6A4 | |
| SCHEMBL14280674 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1DRD2SLC6A4 | |
| SCHEMBL23745568 | 0.70 | OPRL1 (0.47) | OPRL1OPRM1OPRK1CNR1HRH2 | |
| Hydrochloric Acid SCHEMBL23721927 | 0.70 | OPRL1 (0.46) | OPRL1OPRM1OPRK1CNR1HRH2 | |
| SCHEMBL17138491 | 0.66 | MAPT (0.65) | — | |
| SCHEMBL29558412 | 0.66 | MAPT (0.65) | — | |
| SCHEMBL30145551 | 0.66 | MAPT (0.65) | — | |
| SCHEMBL29558790 | 0.66 | MAPT (0.65) | — | |
| SCHEMBL17138584 | 0.66 | MAPT (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRL1 2/4885OPRM1 11/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.